Jaguar Health, Inc. (JAGX) News
Track canonical SquawkNews coverage tagged to JAGX, Jaguar Health, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 9 indexed stories across 7 publication days and is ordered by the same first-publication timeline used by LiveCast.
H
Jaguar Health Receives $2 Million Payment
Jaguar Health gets $2 million payment from Future Pak
EQUITY | Aug 05, 2026, 01:00 PM UTC
L
JAGX - Jaguar Health Reports Positive Consumer and Veterinary Market Research Findings Supporting Commercial Opportunity for Neonorm Dog - C
JAGX - Jaguar Health Reports Positive Consumer and Veterinary Market Research Findings Supporting Commercial Opportunity for Neonorm Dog
EQUITY | Jul 28, 2026, 01:00 PM UTC
L
Jaguar Health announces additional infant to receive crofelemer powder
Jaguar Health announces additional infant to receive crofelemer powder
EQUITY | Jul 22, 2026, 01:10 PM UTC
L
JAGX Jaguar health - napo and alivus enter new manufacturing and supply agreement for crofelemer on July 9, 2026 - SEC filing - 2026 agreeme
JAGX Jaguar health - napo and alivus enter new manufacturing and supply agreement for crofelemer on July 9, 2026 - SEC filing - 2026 agreement includes minimum purchase commitment for crofelemer by napo - SEC filing - 20
REGULATION | Jul 14, 2026, 08:16 PM UTC
L
JAGX Converts Preferred Stock
Jaguar Health announces conversion of Series O convertible preferred stock issued as recent one-time stock dividend
EQUITY | Jun 25, 2026, 01:01 PM UTC
M
JAGX Submits FDA Application
Jaguar Health completes submission of new animal drug application for full FDA approval of Crofelemer for treatment of chemotherapy-induced diarrhea in dogs
EQUITY | Jun 23, 2026, 01:02 PM UTC
M
JAGX Reviews Options
Jaguar Health's board initiates process to review strategic options
EQUITY | Jun 22, 2026, 01:55 PM UTC
H
JAGX Reviews Strategic Alternatives
Jaguar Health's board initiates review of strategic alternatives to maximize shareholder value ahead of NDA filing for Crofelemer candidate.
EQUITY | Jun 22, 2026, 01:10 PM UTC
L
JAGX - Jaguar Health Announces Plan to Explore Strategic Alternatives Aligned with Targeted NDA Filing for Rare Disease Intestinal Failure P
JAGX - Jaguar Health Announces Plan to Explore Strategic Alternatives Aligned with Targeted NDA Filing for Rare Disease Intestinal Failure Program
EQUITY | Jun 22, 2026, 01:02 PM UTC